Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in ...

PDS Biotechnology (PDSB) announced the publication of circulating tumor DNA results for its lead immunotherapy candidate, Versamune HPV, in ...

PDS Biotechnology Corporation (NASDAQ:PDSB) stock has reached a 52-week low, trading at $1.3, as investors navigate a ...

Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.